Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase

被引：0
|
作者：
Skljarevski, Vladimir [1 ]
Stauffer, Virginia L. [1 ]
Zhang, Qi [1 ]
Detke, Holland C. [1 ]
Millen, Brian A. [1 ]
Yang, Jyun Yan [1 ]
Selzler, Katherine J. [1 ]
Conley, Robert [1 ,2 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
CEPHALALGIA | 2017年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PO-01-197
引用
收藏
页码：339 / 340
页数：2
相关论文
共 50 条
  • [41] EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.
    Zhu, Andrew X.
    Kudo, Masatoshi
    Assenat, Eric
    Cattan, Stephane
    Kang, Yoon-Koo
    Lim, Ho Yeong
    Poon, Ronnie Tung Ping
    Blanc, Jean-Frederic
    Vogel, Arndt
    Chen, Chao-Long
    Dorval, Etienne
    Peck-Radosavljevic, Markus
    Santoro, Armando
    Daniele, Bruno
    Furuse, Junji
    Jappe, Annette
    Perraud, Kevin
    Anak, Ozlem
    Sellami, Dalila B.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
    Yoshihisa Tatsuoka
    Takao Takeshima
    Akichika Ozeki
    Taka Matsumura
    Neurology and Therapy, 2021, 10 : 265 - 278
  • [43] Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
    Tatsuoka, Yoshihisa
    Takeshima, Takao
    Ozeki, Akichika
    Matsumura, Taka
    NEUROLOGY AND THERAPY, 2021, 10 (01) : 265 - 278
  • [44] Safety from Phase 3 Clinical Studies Comparing Galcanezumab and Placebo in Patients Episodic and Chronic Migraine
    Bangs, Mark E.
    Kudrow, David
    Wang, Shufang
    Oakes, Tina M.
    Carter, Jeffrey N.
    Terwindt, Gisela M.
    Magis, Delphine
    Stauffer, Virginia L.
    NEUROLOGY, 2019, 92 (15)
  • [45] Prolonged migraine prevention with topiramate (PROMPT): results of the initial 6-month open-label treatment phase
    Lanteri-Minet, M.
    Agosti, R.
    Diener, H-C
    Van Oene, J. C.
    Bergmans, P.
    Schwalen, S.
    CEPHALALGIA, 2006, 26 (11) : 1368 - 1368
  • [46] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Jiying Zhou
    Lianmei Zhong
    Debashish Chowdhury
    Kirill Skorobogatykh
    Guogang Luo
    Xiaosu Yang
    Mingjie Zhang
    Lingli Sun
    Hui Liu
    Chenxi Qian
    Shengyuan Yu
    The Journal of Headache and Pain, 24
  • [47] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Zhou, Jiying
    Zhong, Lianmei
    Chowdhury, Debashish
    Skorobogatykh, Kirill
    Luo, Guogang
    Yang, Xiaosu
    Zhang, Mingjie
    Sun, Lingli
    Liu, Hui
    Qian, Chenxi
    Yu, Shengyuan
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [48] Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine (vol 22, 6, 2021)
    Ament, Michael
    Day, Kathleen
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Rettiganti, Mallikarjuna
    Pearlman, Eric
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [49] Phase-3 safety data from studies comparing galcanezumab and placebo in patients with episodic and chronic migraine
    Stauffer, V. L.
    Wang, S.
    Bangs, M.
    Carter, J.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 298 - 298
  • [50] Elagolix Treatment in Women With Uterine Fibroids: Secondary, 6-Month, Phase 3 Efficacy Results
    Bradley, Linda D.
    Feinberg, Eve C.
    Liu, Ran
    Owens, Charlotte D.
    Rodriguez-Ginorio, Henry
    Simon, James A.
    OBSTETRICS AND GYNECOLOGY, 2019, 133 : 109S - 109S
12345